[The treatment of advanced malignant melanoma with vaccina oncolysates (author's transl)].
Ten patients with recurrent stage II or III malignant melanoma received a live vaccinia virus augmented malignant melanoma cell vaccine. No patient had adverse reactions. The 3 patients surviving (10, 18 and 19 months) had: positive skin reactions to the vaccine (as they had previous positive skin reactions to common recall antigens), elevated vaccinia antibody titers, and they showed lack of progression of the disease with immunotherapy.
D000912:Antibodies, Neoplasm / Q000032:analysis; D000914:Antibodies, Viral / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D007167:Immunotherapy / Q000009:adverse effects; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D014616:Vaccinia virus / Q000276:immunology*; D014780:Viruses
D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D000951:Antigens, Neoplasm
Traitement du mélanome malin évolué par un oncolysat à la vaccine.